Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Trial Comparing the Optimal Timing of Antibiotic Prophylaxis at the Time of Cesarean Delivery

This study has been completed.
University of California, Irvine
Information provided by:
MemorialCare Identifier:
First received: December 17, 2008
Last updated: September 17, 2009
Last verified: September 2009
The purpose of this study is to evaluate the rates of maternal and neonatal infectious morbidity in gravid patients undergoing cesarean delivery. Specifically, the investigators are examining whether the timing of antibiotic administration has any effect on rates of maternal and neonatal infections, neonatal sepsis work-up and length of hospital stay.

Condition Intervention Phase
Cesarean Section
Drug: Cefazolin (Timing of Antibiotic Prophylaxis)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Optimal Timing for Antibiotic Prophylaxis for Elective Cesarean Delivery in Term Gestations: A Randomized, Controlled Trial Comparing Cefazolin Administration Prior to Skin Incision Versus Following Cord Clamping

Resource links provided by NLM:

Further study details as provided by MemorialCare:

Primary Outcome Measures:
  • To assess the rates of maternal infectious morbidity with preoperative administration of antibiotics when compared to antibiotic prophylaxis given following umbilical cord clamping [ Time Frame: 6 weeks ]

Secondary Outcome Measures:
  • To assess incidence of neonatal infectious morbidity (i.e. rates of sepsis work-up, confirmed sepsis, and length of hospital stay) between two study arms [ Time Frame: 6 weeks ]

Enrollment: 50
Study Start Date: August 2008
Study Completion Date: September 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Patients who receive antibiotic prophylaxis after clamping of the umbilical cord
Drug: Cefazolin (Timing of Antibiotic Prophylaxis)
Patients scheduled for a cesarean delivery will be randomly assigned to receive Cefazolin (antibiotic prophylaxis) either prior to skin incision or after the clamping of the umbilical cord
Experimental: 2
Patients who receive antibiotic prophylaxis prior to skin incision
Drug: Cefazolin (Timing of Antibiotic Prophylaxis)
Patients scheduled for a cesarean delivery will be randomly assigned to receive Cefazolin (antibiotic prophylaxis) either prior to skin incision or after the clamping of the umbilical cord

  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Patients 18 years of age or older
  • Any patient at term (>37 weeks gestation) undergoing a scheduled cesarean delivery

Exclusion Criteria:

  • Women younger than 18 years
  • Patients who are febrile during or prior to screening or with a diagnosis of clinical suspicion of endometritis (with or without maternal fever)
  • Patients who present with ruptured membranes
  • Known fetal malformations
  • Contraindications to cefazolin administration (known anaphylactic reaction to penicillins or known cephalosporin allergy)
  • Any exposure to antibiotics in one week prior to cesarean delivery
  • Obstetrical indication for an emergent cesarean delivery
  • Patients taking glucocorticoids or other immunosuppressant therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00811603

United States, California
Long Beach Memorial Medical Center
Long Beach, California, United States, 90806
University of California, Irvine Medical Center
Orange, California, United States, 92868
Sponsors and Collaborators
University of California, Irvine
Principal Investigator: Kenneth Chan, MD Memorial Medical Center
  More Information

Responsible Party: Leo Pevzner, University of California, Irvine Identifier: NCT00811603     History of Changes
Other Study ID Numbers: 474-07
Study First Received: December 17, 2008
Last Updated: September 17, 2009

Keywords provided by MemorialCare:
Antibiotic prophylaxis

Additional relevant MeSH terms:
Anti-Bacterial Agents
Antibiotics, Antitubercular
Anti-Infective Agents
Antitubercular Agents processed this record on May 25, 2017